Loading stock data…
Scribe Therapeutics Inc. (SCTX)
$31.34+2.67 (+9.31%)
Market ClosedLast close Sep 8
Scribe Therapeutics Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $2.23M↓ | $17.13M |
| Gross Profit | — | — |
| Operating Income | -$12.43M↓ | -$5.56M |
| Net Income | -$17.35M↓ | -$3.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$593.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.09%
Volume
Today's trading volume
217,986
Recent News
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic.
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
Gene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation.